On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Comments on DEA’s Removal of Cannabidiol from Schedule 1

  • Phivida’s vision is to help lessen the world’s dependence on pharmaceuticals
  • The company comprises two main brands
  • Phivida recently talked about the removal of CBD from Schedule 1 of the Controlled Substances Act

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is a premium functional food and beverage company. Its focus is whole plant nutrition and natural ingredients. As a result, it infuses organic active hemp extract into an array of premium foods, beverages and clinical products. Phivida’s corporate mission is to help reduce the world’s dependence on pharmaceuticals and provide healthy food and beverage choices. Phivida is headquartered in Vancouver, British Columbia, and has its U.S. office in San Diego, California.

Phivida’s business model consists of two main brands – Vida+ and Oki. Vida+ focuses on providing premium, clinical grade full spectrum hemp oil extracts and capsules that are distributed across the U.S. through alternative health care clinics. Oki is the company’s newly launched lifestyle brand of functional beverages and supplements infused with active hemp extract and will be available to consumers in up to 2,400 natural specialty store locations within the U.S.

Recently, Phivida Holdings talked about the removal of cannabidiol (CBD) from the U.S. Drug Enforcement Administration’s Schedule 1 list of controlled substances. In a news release, Jim Bailey, president and chief executive officer of Phivida, said, “We see this reclassification of CBD in pharmaceuticals as a good sign that will bolster the growing awareness of CBD as a substance that delivers many benefits, and opens the door for other CBD-based treatments, in line with the recent FDA approval of a drug to treat childhood epilepsy.”

The expectation is that the cannabidiol industry will grow to $2 billion by 2022 (http://cnw.fm/4gJZc). New Frontier Data noted that, “The U.S. CBD market is primed for expansive growth across its three primary sectors, hemp-derived CBD, marijuana-derived CBD and pharmaceutical CBD.” Phivida Holdings is leveraging this growth with its innovative new products designed with the discerning consumer in mind. The company’s initiatives, by way of its three subsidiaries, have Phivida on course for exponential growth in a fast-developing sector.

For more information, visit the company’s website at www.Phivida.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722